# Medifast Inc: overview MED · NYSE · CIK 910329 · [Consumer staples](/sectors/consumer-staples.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/med.md) · [Financials](/companies/med/financials.md) · [Filings](/companies/med/filings.md) · [Insiders](/companies/med/insiders.md) Latest reported revenue: [$76.4m](/filings/0001628280-26-051928.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 3, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-051928). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [140](/filings/0001628280-25-048332.md) | [119 d](/filings/0001628280-26-008656.md) | [116](/filings/0001628280-26-029898.md) | [106](/filings/0001628280-26-051928.md) | [89.4](/filings/0001628280-25-048332.md) | [75.1 d](/filings/0001628280-26-008656.md) | [76.0](/filings/0001628280-26-029898.md) | [76.4](/filings/0001628280-26-051928.md) | | Gross margin | % | [75.4%](/filings/0001628280-25-048332.md) | [74.1% d](/filings/0001628280-26-008656.md) | [72.8%](/filings/0001628280-26-029898.md) | [72.6%](/filings/0001628280-26-051928.md) | [69.5%](/filings/0001628280-25-048332.md) | [69.4% d](/filings/0001628280-26-008656.md) | [68.1%](/filings/0001628280-26-029898.md) | [69.9%](/filings/0001628280-26-051928.md) | | Operating margin | % | [1.5%](/filings/0001628280-25-048332.md) | [0.6% d](/filings/0001628280-26-008656.md) | [(1.1%)](/filings/0001628280-26-029898.md) | [(1.0%)](/filings/0001628280-26-051928.md) | [(4.6%)](/filings/0001628280-25-048332.md) | [(10.4%) d](/filings/0001628280-26-008656.md) | [(4.3%)](/filings/0001628280-26-029898.md) | [(5.7%)](/filings/0001628280-26-051928.md) | | Net margin | % | [0.8%](/filings/0001628280-25-048332.md) | [0.7% d](/filings/0001628280-26-008656.md) | [(0.7%)](/filings/0001628280-26-051928.md) | [2.3%](/filings/0001628280-26-051928.md) | [(2.5%)](/filings/0001628280-25-048332.md) | [(24.1%) d](/filings/0001628280-26-008656.md) | [(2.8%)](/filings/0001628280-26-051928.md) | [(4.1%)](/filings/0001628280-26-051928.md) | | Diluted EPS | $ per share | [0.10](/filings/0001628280-25-048332.md) | not reported | [(0.07)](/filings/0001628280-26-029898.md) | [0.22](/filings/0001628280-26-051928.md) | [(0.21)](/filings/0001628280-25-048332.md) | not reported | [(0.19)](/filings/0001628280-26-029898.md) | [(0.28)](/filings/0001628280-26-051928.md) | | Free cash flow | $m | [7.7 d](/filings/0001628280-25-048332.md) | [(7.2) d](/filings/0001628280-26-008656.md) | [1.9](/filings/0001628280-26-029898.md) | [(4.8) d](/filings/0001628280-26-051928.md) | [10.8 d](/filings/0001628280-25-048332.md) | [(6.6) d](/filings/0001628280-26-008656.md) | [(0.8)](/filings/0001628280-26-029898.md) | [0.7 d](/filings/0001628280-26-051928.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1,526](/filings/0001628280-24-005620.md) | [1,599](/filings/0001628280-25-006094.md) | [1,072](/filings/0001628280-26-008656.md) | [602](/filings/0001628280-26-008656.md) | [386](/filings/0001628280-26-008656.md) | | Gross margin | % | [73.9%](/filings/0001628280-24-005620.md) | [71.3%](/filings/0001628280-25-006094.md) | [72.4%](/filings/0001628280-26-008656.md) | [73.8%](/filings/0001628280-26-008656.md) | [71.3%](/filings/0001628280-26-008656.md) | | Operating margin | % | [14.2%](/filings/0001628280-24-005620.md) | [11.6%](/filings/0001628280-25-006094.md) | [11.8%](/filings/0001628280-26-008656.md) | [0.5%](/filings/0001628280-26-008656.md) | [(3.7%)](/filings/0001628280-26-008656.md) | | Net margin | % | [10.7%](/filings/0001628280-24-005620.md) | [9.0%](/filings/0001628280-25-006094.md) | [9.3%](/filings/0001628280-26-008656.md) | [0.3%](/filings/0001628280-26-008656.md) | [(4.8%)](/filings/0001628280-26-008656.md) | | Diluted EPS | $ per share | [13.89](/filings/0001628280-24-005620.md) | [12.73](/filings/0001628280-25-006094.md) | [9.10](/filings/0001628280-26-008656.md) | [0.19](/filings/0001628280-26-008656.md) | [(1.70)](/filings/0001628280-26-008656.md) | | Free cash flow | $m | [60.3](/filings/0001628280-24-005620.md) | [178](/filings/0001628280-25-006094.md) | [141](/filings/0001628280-26-008656.md) | [17.0](/filings/0001628280-26-008656.md) | [1.2](/filings/0001628280-26-008656.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/med/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $8.3m | 778,610 | | Added +4,900 | | [Steamboat Capital Partners, LLC](/funds/1635663.md) | 2026-06-30 | $7.5m | 706,699 | | Reduced −891 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $5.8m | 542,700 | Call | Added +107,300 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $5.1m | 481,381 | | Added +143,223 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $4.7m | 446,614 | | Added +2,147 | | [CHARLES SCHWAB INVESTMENT MANAGEMENT INC](/funds/884546.md) | 2026-06-30 | $4.2m | 396,996 | | Reduced −234,543 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $3.9m | 369,503 | | Reduced −574,950 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $3.9m | 363,394 | | Added +1,632 | | [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $3.4m | 318,911 | | Added +94,631 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $3.1m | 292,508 | | Reduced −32,804 | ## Recent filings [All 961 filings](/companies/med/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-26 | 08:50 ET | [10-Q](/filings/0001628280-26-067165.md) | Quarterly report, period 2026-09-30 | 0001628280-26-067165 | | 2026-10-26 | 08:11 ET | [8-K](/filings/0001628280-26-067151.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-067151 | | 2026-08-21 | 16:01 ET | [SCHEDULE 13D/A](/filings/0001213900-26-092590.md) | Ownership report, active investor, amended | 0001213900-26-092590 | | 2026-08-03 | 16:50 ET | [10-Q](/filings/0001628280-26-051928.md) | Quarterly report, period 2026-06-30 | 0001628280-26-051928 | | 2026-08-03 | 16:12 ET | [8-K](/filings/0001628280-26-051845.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-051845 | | 2026-07-17 | 08:33 ET | [8-K](/filings/0001628280-26-048574.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-048574 | | 2026-06-01 | 08:59 ET | [8-K](/filings/0001628280-26-039293.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001628280-26-039293 | | 2026-05-26 | 16:26 ET | [8-K](/filings/0001628280-26-038109.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-038109 | | 2026-05-04 | 16:51 ET | [10-Q](/filings/0001628280-26-029898.md) | Quarterly report, period 2026-03-31 | 0001628280-26-029898 | | 2026-05-04 | 16:12 ET | [8-K](/filings/0001628280-26-029812.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-029812 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-008656.md), filed Feb 17, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, locked when the 8-K was accepted. It is scored when the 10-Q or 10-K is ingested. [See the target](/leagues/2026q3/targets/b5916a9f-2a26-4b5e-b89a-461e021b9fe2) ## About the filer - CIK: 910329 - Tickers: MED - Exchange: NYSE - SIC code: 2090 Miscellaneous Food Preparations & Kindred Products - State of incorporation: DE - Filer category: Accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 12:57 ET. No prices; not investment advice.